The Phase 1 human clinical trials of Hyderabad-based vaccine maker Bharat Biotech’s intranasal Covid-19 vaccine, codenamed BBV154, have commenced at some of the selected sites that include Hyderabad and Nagpur.
Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a manufacturing giant of vaccines, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets.
Washington University School of Medicine in St. Louis has developed a saliva-based test for COVID-19 that is faster and easier than the swab tests currently in use. The test could help simplify and expand the availability of COVID-19 diagnostic testing across broad populations.